| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Total revenue | 15,603 | 10,906 | -5,423* | 7,406 |
| Cost of goods sold | 3,610 | 1,673 | -2,960* | 2,316 |
| Selling, general and administrative | 27,673 | 21,104 | 2,321* | 19,628 |
| Research and development | 600 | 186 | 238* | 145 |
| Amortization of intangible assets | 1,043 | 1,031 | -481* | 679 |
| Total operating expenses | 32,926 | 23,994 | -882* | 22,768 |
| Operating loss | -17,323 | -13,088 | -4,541* | -15,362 |
| Interest expense | 2,389 | 2,353 | 753* | - |
| Impairment of intangible assets | - | - | 71* | - |
| Interest expense | - | - | - | 1,346 |
| Change in fair value of convertible debt | -3,705 | -9,632 | -15,103* | - |
| Interest income and other income | - | - | -10* | 5 |
| Total other expense | -6,094 | -11,985 | -15,937* | -1,341 |
| Net loss before provision for income taxes | -23,417 | -25,073 | -20,478* | -16,703 |
| Provision for income taxes | 0 | 0 | -6,689* | -465 |
| Net loss | -23,417 | -25,073 | -13,789 | - |
| Change in fair value of convertible debt due to instrument credit risk | -110 | 2,188 | - | - |
| Net loss and comprehensive loss | - | - | - | -16,238 |
| Comprehensive loss | -23,527 | -22,885 | - | - |
| Basic EPS | -6.62 | -7.57 | -7.332 | -5.3 |
| Diluted EPS | -6.62 | -7.57 | -7.332 | -5.3 |
| Basic Average Shares | 3,539,464 | 3,311,742 | 1,880,498* | 3,061,488 |
| Diluted Average Shares | 3,539,464 | 3,311,742 | 1,880,498* | 3,061,488 |
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)